Catalyst Wire Dossier Catalyst Wire Dossier

ULTOMIRIS

ravulizumab · Alexion Pharmaceuticals Inc.
Drug timelines are a Plus or Pro feature.

27 regulatory and trial events tracked for ULTOMIRIS, covering 2018-12-21 to 2026-07-21. Get the full timeline:

Most recent: EMA Authorised: Ultomiris (ravulizumab) — Alexion Europe SAS

See pricing